The clinical significance of receiving a kidney allograft from deceased donor with chronic histologic changes.
Journal
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
ISSN: 1530-0285
Titre abrégé: Mod Pathol
Pays: United States
ID NLM: 8806605
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
21
12
2020
accepted:
04
04
2021
revised:
03
04
2021
pubmed:
15
5
2021
medline:
27
1
2022
entrez:
14
5
2021
Statut:
ppublish
Résumé
Allograft survival of deceased donor kidneys with suboptimal histology (DRTx/suboptimal histology: >10% glomerulosclerosis, >10% tubulointerstitial scarring, or >mild vascular sclerosis) is inferior to both DRTx with optimal histology (DRTx/optimal histology) and living donor kidneys irrespective of histologic changes (LRTx). In this report, we explored the reasons behind this guarded outcome with a special focus on the role of alloimmunity. We initially assessed gene expression in 39 time-zero allograft biopsies using the Nanostring 770 genes PanCancer Immune Profiling Panel. Subsequently, we studied 696 consecutive adult kidney allograft recipients that were grouped according to allograft type and histology at time-zero biopsy [DRTx/suboptimal histology (n = 194), DRTx/optimal histology (n = 166), and LRTx (n = 336)]. Part-1: Several immune pathways were upregulated in time-zero biopsies from DRTx/suboptimal histology (n = 11) compared to LRTx (n = 17) but not to DRTx/optimal histology (n = 11). Part-2: Amongst the three groups of recipients, DRTx/suboptimal histology had the highest incidence of acute rejection episodes, most of which occurred during the first year after transplantation (early rejection). This increase was mainly attributed to T cell mediated rejection, while the incidence of antibody-mediated rejection was similar amongst the three groups. Importantly, early acute T cell mediated rejection was a strong independent predictor for allograft failure in DRTx/suboptimal histology (adjusted HR: 2.13, P = 0.005) but not in DRTx/optimal histology nor in LRTx. Our data highlight an increased baseline immunogenicity in DRTx/suboptimal histology compared to LRTx but not to DRTx/optimal histology. However, our results suggest that donor chronic histologic changes in DRTx may help transfer such increased baseline immunogenicity into clinically relevant acute rejection episodes that have detrimental effects on allograft survival. These findings may provide a rationale for enhanced immunosuppression in recipients of DRTx with baseline chronic histologic changes to minimize subsequent acute rejection and to prolong allograft survival.
Identifiants
pubmed: 33986461
doi: 10.1038/s41379-021-00815-9
pii: S0893-3952(22)00557-9
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1795-1805Subventions
Organisme : NHLBI NIH HHS
ID : T32 HL007854
Pays : United States
Informations de copyright
© 2021. The Author(s), under exclusive licence to United States & Canadian Academy of Pathology.
Références
Aubert O, Reese PP, Audry B, Bouatou Y, Raynaud M, Viglietti D, et al. Disparities in acceptance of deceased donor kidneys between the United States and France and estimated effects of increased US acceptance. JAMA Intern Med. 2019;179:1365–74.
doi: 10.1001/jamainternmed.2019.2322
Husain SA, Chiles MC, Lee S, Pastan SO, Patzer RE, Tanriover B, et al. Characteristics and performance of unilateral kidney transplants from deceased donors. Clin J Am Soc Nephrol. 2018;13:118–27.
doi: 10.2215/CJN.06550617
Mohan S, Foley K, Chiles MC, Dube GK, Patzer RE, Pastan SO, et al. The weekend effect alters the procurement and discard rates of deceased donor kidneys in the United States. Kidney Int. 2016;90:157–63.
doi: 10.1016/j.kint.2016.03.007
Mohan S, Chiles MC, Patzer RE, Pastan SO, Husain SA, Carpenter DJ, et al. Factors leading to the discard of deceased donor kidneys in the United States. Kidney Int. 2018;94:187–98.
doi: 10.1016/j.kint.2018.02.016
Carpenter D, Husain SA, Brennan C, Batal I, Hall IE, Santoriello D, et al. Procurement biopsies in the evaluation of deceased donor kidneys. Clin J Am Soc Nephrol. 2018;13:1876–85.
doi: 10.2215/CJN.04150418
Cecka, JM. The OPTN/UNOS renal transplant registry. Clin Transpl., 2005;1–16.
Nemati E, Einollahi B, Lesan Pezeshki M, Porfarziani V, Fattahi MR. Does kidney transplantation with deceased or living donor affect graft survival? Nephrourol Mon. 2014;6:e12182.
pubmed: 25695017
pmcid: 4317718
Mohan S, Campenot E, Chiles MC, Santoriello D, Bland E, Crew RJ, et al. Association between reperfusion renal allograft biopsy findings and transplant outcomes. J Am Soc Nephrol. 2017;28:3109–17.
doi: 10.1681/ASN.2016121330
Gaston RS. Our evolving understanding of late kidney allograft failure. Curr Opin Organ Transpl. 2011;16:594–9.
doi: 10.1097/MOT.0b013e32834c23a7
Tomfohr J, Lu J, Kepler TB. Pathway level analysis of gene expression using singular value decomposition. BMC Bioinforma. 2005;6:225.
doi: 10.1186/1471-2105-6-225
Haeggblom L, Ahrlund-Richter A, Mirzaie L, Farrajota Neves da Silva P, Ursu RG, Ramqvist T, et al. Differences in gene expression between high-grade dysplasia and invasive HPV(+) and HPV(-) tonsillar and base of tongue cancer. Cancer Med. 2019;8:6221–32.
doi: 10.1002/cam4.2450
Norton N, Advani PP, Serie DJ, Geiger XJ, Necela BM, Axenfeld BC, et al. Assessment of tumor heterogeneity, as evidenced by gene expression profiles, pathway activation, and gene copy number, in patients with multifocal invasive lobular breast tumors. PLoS One. 2016;11:e0153411.
doi: 10.1371/journal.pone.0153411
Racusen LC, Solez K, Colvin RB, Bonsib SM, Castro MC, Cavallo T, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int. 1999;55:713–23.
doi: 10.1046/j.1523-1755.1999.00299.x
Loupy A, Haas M, Roufosse C, Naesens M, Adam B, Afrouzian M, et al. The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell- and antibody-mediated rejection. Am J Transpl. 2020;20:2318–31.
doi: 10.1111/ajt.15898
McRae M, Bouchard-Boivin F, Beland S, Noel R, Cote I, Lapointe I, et al. Impact of the current versus the previous diagnostic threshold on the outcome of patients with borderline changes suspicious for T cell-mediated rejection diagnosed on indication biopsies. Transplantation. 2018;102:2120–5.
doi: 10.1097/TP.0000000000002327
Dale LA, Brennan C, Batal I, Morris H, Jain NG, Valeri A, et al. Treatment of borderline infiltrates with minimal inflammation in kidney transplant recipients has no effect on allograft or patient outcomes. Clin Transplant. 2020. e14019. https://doi.org/10.1111/ctr.14019 .
Cooper JE. Evaluation and treatment of acute rejection in kidney allografts. Clin J Am Soc Nephrol. 2020;15:430–8.
doi: 10.2215/CJN.11991019
Land WG. Emerging role of innate immunity in organ transplantation part II: potential of damage-associated molecular patterns to generate immunostimulatory dendritic cells. Transpl Rev. 2012;26:73–87.
doi: 10.1016/j.trre.2011.02.003
Nakamura K, Kageyama S, Kupiec-Weglinski JW. Innate immunity in ischemia-reperfusion injury and graft rejection. Curr Opin Organ Transpl. 2019;24:687–93.
doi: 10.1097/MOT.0000000000000709
Pratschke J, Wilhelm MJ, Kusaka M, Beato F, Milford EL, Hancock WW, et al. Accelerated rejection of renal allografts from brain-dead donors. Ann Surg. 2000;232:263–71.
doi: 10.1097/00000658-200008000-00017
Yang J, Snijders MLH, Haasnoot GW, van Kooten C, Mallat M, de Fijter JW, et al. Elevated intragraft expression of innate immunity and cell death-related markers is a risk factor for adverse graft outcome. Transpl Immunol. 2018;48:39–46.
doi: 10.1016/j.trim.2018.02.009
uillen-Gomez E, Dasilva I, Silva I, Arce Y, Facundo C, Ars E, et al. Early macrophage infiltration and sustained inflammation in kidneys from deceased donors are associated with long-term renal function. Am J Transpl. 2017;17:733–43.
doi: 10.1111/ajt.13998
Kotsch K, Kunert K, Merk V, Reutzel-Selke A, Pascher A, Fritzsche F, et al. Novel markers in zero-hour kidney biopsies indicate graft quality and clinical outcome. Transplantation. 2010;90:958–65.
doi: 10.1097/TP.0b013e3181f546e8
Naesens M, Li L, Ying L, Sansanwal P, Sigdel TK, Hsieh SC, et al. Expression of complement components differs between kidney allografts from living and deceased donors. J Am Soc Nephrol. 2009;20:1839–51.
doi: 10.1681/ASN.2008111145
Kruger B, Krick S, Dhillon N, Lerner SM, Ames S, Bromberg JS, et al. Donor Toll-like receptor 4 contributes to ischemia and reperfusion injury following human kidney transplantation. Proc Natl Acad Sci USA. 2009;106:3390–5.
doi: 10.1073/pnas.0810169106
Kaminska D, Tyran B, Mazanowska O, Rabczynski J, Szyber P, Patrzalek D, et al. Cytokine gene expression in kidney allograft biopsies after donor brain death and ischemia-reperfusion injury using in situ reverse-transcription polymerase chain reaction analysis. Transplantation. 2007;84:1118–24.
doi: 10.1097/01.tp.0000287190.86654.74
Veldman-Jones MH, Brant R, Rooney C, Geh C, Emery H, Harbron CG, et al. Evaluating robustness and sensitivity of the nanostring technologies ncounter platform to enable multiplexed gene expression analysis of clinical samples. Cancer Res. 2015;75:2587–93.
doi: 10.1158/0008-5472.CAN-15-0262
Balko JM, Cook RS, Vaught DB, Kuba MG, Miller TW, Bhola NE, et al. Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. Nat Med. 2012;18:1052–9.
doi: 10.1038/nm.2795
Mengel M, Loupy A, Haas M, Roufosse C, Naesens M, Akalin E, et al. Banff 2019 Meeting Report: Molecular diagnostics in solid organ transplantation-Consensus for the Banff Human Organ Transplant (B-HOT) gene panel and open source multicenter validation. Am J Transpl. 2020;20:2305–17.
doi: 10.1111/ajt.16059
Zhang W, Zhao J, Cao F, Li S. Regulatory effect of immunosuppressive agents in mice with renal ischemia-reperfusion injury. Exp Ther Med. 2018;16:3584–8.
pubmed: 30233712
pmcid: 6143854
Moradzadeh K, Nassiri SM, Gheisari Y. Valproic acid restores the down-regulation of SDF-1 following kidney ischemia; experimental validation of a mathematical prediction. Res Pharm Sci. 2020;15:191–9.
doi: 10.4103/1735-5362.283819
Batal I, De Serres SA, Safa K, Bijol V, Ueno T, Onozato ML, et al. Dendritic cells in kidney transplant biopsy samples are associated with T cell infiltration and poor allograft survival. J Am Soc Nephrol. 2015;26:3102–13.
doi: 10.1681/ASN.2014080804
de Fijter JW, Mallat MJ, Doxiadis II, Ringers J, Rosendaal FR, Claas FH, et al. Increased immunogenicity and cause of graft loss of old donor kidneys. J Am Soc Nephrol. 2001;12:1538–46.
doi: 10.1681/ASN.V1271538
Nankivell BJ, Chapman JR. Chronic allograft nephropathy: current concepts and future directions. Transplantation. 2006;81:643–54.
doi: 10.1097/01.tp.0000190423.82154.01
Land WG. Ageing and immunosuppression in kidney transplantation. Exp Clin Transpl. 2004;2:229–37.
Huisman A, Vos I, van Faassen EE, Joles JA, Grone HJ, Martasek P, et al. Anti-inflammatory effects of tetrahydrobiopterin on early rejection in renal allografts: modulation of inducible nitric oxide synthase. FASEB J. 2002;16:1135–7.
doi: 10.1096/fj.01-0890fje